Alyeska reports 4.67% Cabaletta Bio stake

Cabaletta Bio received an updated ownership report from Alyeska-affiliated entities and Anand Parekh.

Accepted by SEC EDGAR 02/17/2026 - 04:33 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cabaletta Bio received an updated ownership report from Alyeska-affiliated entities and Anand Parekh. They report beneficial ownership of 4,500,000 shares of Cabaletta Bio common stock through warrants, representing 4.67% of the company’s common stock, based on 96,265,204 shares outstanding as disclosed in a recent Form 10-Q.

The filing shows no sole voting or dispositive power, but shared power over all 4,500,000 shares. The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cabaletta Bio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in Cabaletta Bio (CABA) is reported by Alyeska and Anand Parekh?

The filing reports beneficial ownership of 4,500,000 Cabaletta Bio common shares through warrants, representing 4.67% of the company’s common stock. This percentage is calculated using 96,265,204 shares outstanding as reported in Cabaletta Bio’s Form 10-Q filed November 10, 2025.

How do Alyeska and related parties hold their Cabaletta Bio (CABA) position?

Alyeska and related reporting persons hold warrants to purchase 4,500,000 Cabaletta Bio common shares. These warrants give them shared voting and dispositive power over that amount of stock, rather than holding the shares outright, as described in the exhibit to the Schedule 13G/A amendment.

Is the Cabaletta Bio (CABA) stake held with the intent to influence control?

The reporting persons certify the Cabaletta Bio securities were acquired and are held in the ordinary course of business. They explicitly state the holdings are not for the purpose of changing or influencing control of Cabaletta Bio and are not part of a control-related transaction.

Which entities and individuals are listed as reporting persons for Cabaletta Bio (CABA)?

The Schedule 13G/A lists Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh as joint reporting persons. Each is shown with the same 4,500,000 shares beneficially owned and the same 4.67% of Cabaletta Bio’s outstanding common stock class.

What voting and dispositive powers are reported over Cabaletta Bio (CABA) shares?

The report indicates no sole voting or dispositive power over Cabaletta Bio shares. Instead, the reporting persons have shared voting power and shared dispositive power over 4,500,000 shares, matching the full amount of beneficial ownership reported in the Schedule 13G/A.

How was the 4.67% ownership in Cabaletta Bio (CABA) calculated?

The 4.67% figure is based on 4,500,000 shares beneficially owned relative to 96,265,204 Cabaletta Bio common shares outstanding. The outstanding share count comes from Cabaletta Bio’s Form 10-Q filed with the SEC on November 10, 2025, as referenced in the exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

CABALETTA BIO, INC.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

12674W109

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 12674W109

1

Names of Reporting Persons

Alyeska Investment Group, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,500,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,500,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.67 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 12674W109

1

Names of Reporting Persons

Alyeska Fund GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,500,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,500,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.67 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 12674W109

1

Names of Reporting Persons

Anand Parekh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,500,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,500,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.67 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CABALETTA BIO, INC.
(b)	Address of issuer's principal executive offices: 2929 Arch Street, Suite 600, Philadelphia, PA 19104
Item 2.
(a)	Name of person filing: (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh
(b)	Address or principal business office or, if none, residence: (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601
(c)	Citizenship: (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 12674W109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,500,000
(b)	Percent of class: 4.67%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 4,500,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 4,500,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alyeska Investment Group, L.P.

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Alyeska Fund GP, LLC

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Anand Parekh

Signature:	Anand Parekh
Name/Title:	Anand Parekh | Self
Date:	02/17/2026

Exhibit Information

The reporting persons hold warrants to purchase 4,500,000 shares of the Issuer's Common Stock (the "Warrants"). The percentage of beneficial ownership is based on 96,265,204 shares of the registrant's common stock outstanding as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 10, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.